Please Wait...

Expert Biomarker Services For Alzheimer's Disease Research

Alzheimer's Disease (AD), a fatal neurodegenerative disorder characterized by progressive cognitive impairment and memory loss, is the major cause of dementia. The two main neuropathological hallmarks of AD are extracellular amyloid plaques, and neurofibrillary tangles (NTFs), primarily composed of the protein tau.

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a normal or pathological process, or as a measure of response to therapy. Application of cerebrospinal fluid-based (CSF) and blood-based biomarkers in clinical research has revolutionized the understanding of AD. Especially, detection of Aβ and tau in CSF has led to crucial advancements in disease detection at its earliest stage (Fig 1).

In general, biomarkers have proven extremely useful throughout the different steps of AD clinical trials: patient inclusion and enrichment, and evaluation of target engagement and clinical efficacy of therapeutic drugs. Changes in CSF and blood-based biomarkers reflect different pathological processes in AD.

Informed Decision-Making. Quality Data. Improved Outcomes.

Bioclinica AD biochemical marker capabilities:

  • Fit-for-Purpose Validation
  • Expertise in Sample Handling
  • Centralized analysis to minimize assay variability
  • Controlled storage of biological samples
  • Established partnership with internationally recognized KOL
  • AD specific Proficiency Testing Program

 

Fluid-based biomarkers can facilitate development of new AD therapies by allowing:

  • Enrichment and stratification of patients
  • Evaluation of target engagment
  • Measurement of disease progression
  • Clinical efficacy and safety assessment of therapeutic drugs

 

Download our AD Biomarker Expertise Sheet

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

[Fun Friday] Now that's using you noodle! Ck this out in @RandDMagazine https://t.co/o5h9O1ScBF
bioclinica (7 hours ago)
FDA, NIH & Industry Advance Templates for Clinical Trial Protocols | RAPS https://t.co/Cqda7fLQZf
bioclinica (Yesterday)
Significant Safety Events Found in a Third of FDA-Approved Drugs, Study Finds | RAPS https://t.co/mAHe42W4or
bioclinica (Yesterday)
FDA Official Highlights Foreign Supply Chain Challenges | RAPS https://t.co/qHDtoRw9MS
bioclinica (Yesterday)
RT @MySCRS: Survey finds 50% of Americans are unaware of #ClinicalTrials, reported by @EdClinical. https://t.co/57x8gtXRT0
bioclinica (Yesterday)
RT @ACROhealth: Recent poll data from @ResearchAmerica, 59% of those polled said their family’s health has been improved by clinical resear…
bioclinica (Yesterday)

Latest Blogs: